Not exact matches
Moody's Investor Services says spending pressure will challenge the province's ability to «
sustain balanced fiscal results»
over a
number of years.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full
year 2018 financial results; Gilead's ability to
sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the
number of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products
over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Engineering construction activity has nearly doubled
over the past two
years and this upswing is likely to be
sustained in the period ahead, with a
number of significant road and mining - related projects scheduled for commencement in 2004 (Graph 41).
Both Mouton Cadet and the America's Cup are world - leading brands which have been built
over many
years through the dedication
of committed teams who pull together to achieve and
sustain the
number one position.»
Publication
of the Purdue study sent shock - waves reverberating through the football world, with the findings cited by concussion experts calling on youth sports organizations to take more aggressive action to minimize exposure to RHI, including sub-concussive blows, by changing the way contact and collision sports are played and practiced, and reducing the amount
of brain trauma a child incurs by limiting the
number of hits they
sustain in a sports season,
over the course
of a
year, and during a career.
The original, randomized, open label study, which enrolled 20 outpatient men with cirrhosis and recurrent HE receiving standard -
of - care (SOC) treatment, had previously reported that a single FMT enema after antibiotic pretreatment improved cognitive function at Day 20 and reduced HE episodes and hospitalizations
over the following 5 months compared with SOC.1 The long - term outcomes
of this study, which were presented today at The International Liver Congress ™ 2018 in Paris, France, demonstrated
sustained and statistically significant reductions in the
number of HE episodes and hospitalizations as well as improvements in cognitive function
over 1
year in the men who received FMT compared with the control group.
She added that the impressive sales
numbers for the first six books
of The Godling Chronicles series in both audiobook and ebook formats, and their
sustained sales
over the past four
years, convinced Audible that even a six - figure advance was not much
of a risk.
This does not mean the lawyer or law firm has won every case, but rather has
sustained a successful personal injury practice
over a
number of years.
A study
of individual cognitive therapy for bipolar disorder showed positive outcomes at 1 -
year follow - up, but the benefits were reduced
over time, suggesting the need for booster sessions to
sustain the gains.19 As with many forms
of therapy, CBT has been found to be more successful in reducing relapse in the depressive pole compared with the manic pole.30 A large randomised trial
of CBT showed no difference between CBT and treatment as usual, when all participants were included in the analyses.31 However, results
of a post-hoc analysis suggested that CBT was effective for participants who reported fewer than 12 prior episodes
of illness and were not acutely unwell when therapy began;
numbers of episodes
of mania rather than depression seemed to predict treatment response.32 Such data can help guide the clinical application
of CBT for bipolar patients.